Opens in new window
Site map
- Home
- Destination 2033
- About us
- News
- Contact
- Topics
- Welsh Blood Service
- Velindre Cancer Service
- Inpatients
- Outpatients
- Patient Information
- Systemic Anti Cancer Therapy (SACT) leaflets
- General Information
- Systemic Anti Cancer Therapy (SACT) Patient Information leaflets
- CVP 232
- Weekly 5FU
- Carboplatin and Taxol
- Dabrafenib 850
- Zometa 269
- General Chemotherapy
- Dacarbazine 195
- Zometa A1057
- Nivolumab and Relatlimab (Opdualag)
- Denosumab 656
- Zomorph Capsules for oral and NG administration - directions for opening
- Atezolizumab and Abraxane A1701
- Docetaxel and Cyclophosphomide 479
- Carboplatin and 5FU
- Docetaxel and OxMdG1 A1042
- Zometa 269
- Docetaxel and nintedanib 907
- vinorelbine
- Docetaxel (Taxotere TM) 78,347 & 361
- VIDE
- Doxorubicin
- Transport
- Durvalumab A1048
- Topotecan
- ECarboX 374
- temozolomide
- ECarboF 377
- Scalp Cooling
- ECF 4
- Information leaflet about R-CHOP
- ECF 362
- pemetrexed and cisplatin
- ECX 277
- pemetrexed and carboplatin
- EOX 276
- paclitaxel
- Entrectinib A1254
- Information sheet on paclitaxel (Taxol) and carboplatin
- Encorafenib and Cetuximab A1294
- Oxaliplatin 5 Fluorouracil (5-FU) and folinic acid
- Encorafenib and Cetuximab A1294
- Nivolumab
- Enzalutamide 690
- Cisplatin and Capecitabine 363
- Eribulin 647
- Carboplatin and 5 Fluorouracil (5-FU) 270
- Erlotinib (Tarceva) 449
- Modified deGramont 175
- Etoposide 338
- Information sheet on zoledronic acid (Zometa) in Early Breast Cancer
- Etoposide, Doxorubicin and Cisplatin chemotherapy 670
- Eribulin 647
- Everolimus 484
- Pembrolizumab, Paclitaxel, Carboplatin, Epirubicin and Cyclophosphamide
- FEC 14 and 422
- Cisplatin and 5FU 158 A1232
- FEC-T 388 and 476
- Epirubicin, Cyclophosphamide and Paclitaxel A1023, A1601, A1228, A1229
- Gemcitabine 244 and 81
- Pembrolizumab and Lenvatinib A1553
- Gemcitabine and abraxane (Nab-Paclitaxel)
- A1615 Carboplatin and Abraxane
- Gemcitabine and capecitabine chemotherapy 320
- DPD testing for patient receiving 5FU or Capecitabine
- Gemcitabine and carboplatin 322
- EC-T
- Gemcitabine and docetaxel 597
- Alpelsib A1332
- Gem-P 456
- Adjuvant Abemaciclib A1540
- A1540 Adjuvant Abemaciclib
- IAd 43
- Breast cancer – hormonal therapy
- Imatinib 333
- Hormonal therapy for breast cancer
- Interferon 406
- Hair Loss Leaflet
- Ipilimumab and nivolumab 969, A1078
- Dostarlimab A1503
- Ipilimumab 589
- Tucatinib and Capecitabine A1507
- Irinotecan 341 and 342
- Atezolizumab and Bevacizumab A1345
- Irinotecan and capecitabine 296 and 318
- Capecitabine and Tucatinib A1507
- Irinotecan and vincristine A1052
- IrMdG and cetuximab 527
- A1421 Information leaflet on Sacituzumab Govitecan (Trodelvy®)
- IrMdG 179
- Encorafenib and Binimetinib
- IrOxMdG 526
- Cisplatin
- Kadclya® (Trastumzumab Emtansine)
- Pemetrexed
- Lenvatinib 977
- CAV
- Lorlatanib
- Sorafenib
- Lonsurf (Tas-102) 940
- Sunitinib
- Macmillan Cancer Unit - Prince Charles
- Masitinib 819
- Apalutamide A1236
- Mitomycin (5-FU) 264 and 910
- Abemaciclib A1142
- Modified deGramont 175
- Abraxane 485 & 489
- MV Carbo 328
- Abiraterone
- Nevill Hall - Outreach Clinic
- ABT 414 (Abbvie)
- Niraparib A1034
- Afatinib
- Nivolumab 932, A1070 and A1118
- Aflibercept and irinotecan 5 floroucracil
- Olaparib (899, A1128)
- Alectinib (A1102)
- Olaratumab and doxorubicin 987
- Atelzolizumab A1041
- Osimertinib 926
- Avelumab A1065
- Oxaliplatin and capecitabine 289 and 324
- Axitinib 665
- Oxaliplatin and raltitrexed 561
- Bendamustine 533
- Paclitaxel (Taxol) and carboplatin 754
- R-Bendamustine chemotherapy 773
- Palbociclib
- BEP 67
- Panitumumab with oxaliplatin, 5 fluorouracil and folinic acid (OxMdG) A1047
- Bevacizumab 346
- Panzopanib 624
- Cabazitaxel 755
- Pembrolizumab (836 + A1004)
- Caelyx 309
- Pemetrexed and carboplatin 570
- Caelyx and carboplatin 413
- Pemetrexed and cisplatin 354
- Capecitabine and mitomycin chemotherapy and radiotherapy 631
- Pixantrone 823
- Carboplatin 5 and 205
- Princess of Wales
- Carboplatin and 5 fluorouracil (5-FU) chemotherapy 270
- Procarbazine, lomustine and vincristine 95
- Carboplatin & capecitabine 373 and 608
- Ramucirumab 917
- Carboplatin and docetaxel 167
- Regorafenib 717
- Carboplatin and etoposide 103 and 321
- Ribociclib A1043
- Carboplatin and vinorelbine 514 and 515
- R-CHOP 410 & 842
- Carboplatin - testicular cancer 91
- Royal Glamorgan Outreach
- Cabozantinib 979 & A1113
- Rucaparib A1069
- Capecitabine 236
- Scalp cooling
- Capecitabine and mitomycin 327
- St David's Hospice
- Capecitabine and temozolmide 822
- Subcutaneous herceptin 786
- Capecitabine RT 325 and 674
- Subcutaneous Trastuzumab and Pertuzumab (Phesgo®)
- CCEP 248
- Supportive Care Team (link)
- Cemiplimab A1199
- Switch from Herceptin to Ontruzant (Trastuzumab)
- Ceritinib 978
- Paclitaxel (Taxol) and carboplatin 54, 547 and 652
- Cetuximab 340
- T Carbo F 679
- Cetuximab and cisplatin 5FU A1027
- TPF 415 (inpatient)
- Cetuximab and OxMdG 578
- Tenovus mobile unit
- Cisplatin & 5FU with radiotherapy 201
- Tivozanib A1061
- Cisplatin and capecitabine with RT 363
- Tomozolomide 329 and 355
- Cisplatin and Capecitabine chemotherapy 363
- Topotecan 115
- Cisplatin and etoposide 450
- Topotecan and cisplatin 860
- Cisplatin and gemcitabine 292 & 358
- Trabectedin 330 and 668
- Cisplatin and RT 27
- Trastuzumab (315, A1109, A1110, A1111, A1112)
- Cisplatin and vinorelbine TM 571
- Trastuzumab deruxtecan (Enhertu®) A1373
- Cisplatin and teysuno 857
- Trastuzumab and pertuzumab 748, A1092 and A1093
- Cisplatin and RT 180 and 243
- Transport - patient
- Cisplatin (inpatient) & 5-FU 201,271 and 272
- VAI - Available from CRUK
- Continual infusion 5FU and mitomycin
- VIDE 224
- CMF - available from Macmillan
- Vinorelbine 356
- Headstrong
- Local support groups
- Useful websites
- Bereavement Information
- Carers information
- Dementia Information
- Dietary Information
- Radiotherapy Information leaflets
- Contact
- Treatment helpline
- Our services
- Directories
- Getting here
- Visiting
- Engage with us
- Transforming Cancer Services
- Charity